Current Landscape of iPSC Haplobanks

Area of Science:

• Regenerative Medicine
• Immunology
• Stem Cell Biology

Background:

• Allogeneic cell therapies using induced pluripotent stem cells (iPSCs) present a cost-effective alternative to patient-specific treatments.
• Human Leukocyte Antigen (HLA)-homozygous iPSCs can minimize immune rejection in cell therapies.
• Existing and developing HLA-homozygous iPSC haplobanks aim to supply clinical-grade materials for diverse populations.

Purpose of the Study:

• To review current global initiatives in establishing HLA-homozygous iPSC haplobanks.
• To highlight the potential benefits of these haplobanks for regenerative medicine.
• To discuss strategies for harmonizing quality standards and global accessibility.

Main Methods:

• Review of existing literature and ongoing projects on HLA-homozygous iPSC haplobanks.
• Analysis of strategies for quality control and standardization in cell banking.
• Exploration of population coverage and accessibility of HLA-matched cell therapies.

Main Results:

• Multiple HLA-homozygous iPSC haplobanks are operational or in development worldwide.
• These haplobanks aim to cover frequent HLA haplotypes in specific populations.
• Standardization and a global registry could enhance collective efforts and patient access.

Conclusions:

• HLA-homozygous iPSC haplobanks are crucial for advancing allogeneic cell therapies.
• Harmonization of quality standards and global collaboration are essential for broad patient benefit.
• These initiatives promise wider access to HLA-compatible cell therapies, reducing immune rejection and costs.